OVERVIEW
Accelerate MS trial success with confident, actionable data
Multiple Sclerosis is complex – your trial strategy shouldn’t be. With more than 5,000 neurological trials and 24 approved MS therapies supported, Clario brings proven tools, scientific expertise, and operational support to simplify complexity and deliver what matters: reliable data, confident decisions, and faster progress.
By integrating NeuroRx’s deep imaging expertise, we’ve built a powerful, MS-focused solution that helps you move from uncertainty to clarity, from protocol to approval, with confidence.
We are trusted by global sponsors because we’ve:
- Supported over 5,000 neurology trials
- Delivered data for 24 approved MS treatments
- Partnered with Mobilise-D to set the standard in digital mobility outcomes
SOLUTIONS AND EXPERTISE
Smart solutions that drive outcomes
Have greater confidence at submission with strong evidence and clear endpoints
- Detect what matters – Identify and quantify lesions associated with relapsing or progressive biology with semi-automated tools that reduce interpretation variability and support early signal detection.
- Track neurodegeneration – Access chronic active lesions and volumetric brain data using industry gold standards for validated, regulatory-accepted metrics.
- Go beyond the visible – Assess microstructural changes to uncover subtle therapeutic effects that standard imaging may miss.
Protect patients with built-in safety oversight
Make confident go/no-go decisions, minimize surprises, and help maintain patient safety.
- Protect patients and stay ahead of risks – Centralized ECG and pulmonary monitoring built for MS trials detect issues early – before they derail timelines or impact safety.
- Streamline oversight without slowing down sites – Therapeutic area experts design protocols that reduce site burden while maintaining high safety standards.
- Act fast with a full, real-time safety view – All cardiac and respiratory data flows into one platform – so you see what matters, when it matters.
Deliver EDSS data you can trust
Maintain data integrity and reduce site burden with more consistent EDSS scoring.
- Standardize scoring – Certify raters upfront to drive consistency across every site.
- Boost reliability – Use central review by University Hospital Basel (UHB) to reduce variability and strengthen data accuracy.
- Catch issues early – Flag outliers in real time with algorithm-based data monitoring (ABDM).
- Lighten the load – Streamline data collection with electronic workflows that cut site and sponsor burden.
Capture progress where it happens – in the real world
Track progression with greater sensitivity, detect earlier efficacy signals, and reduce data noise.
- Get beyond snapshots – Our Opal wearable sensors continuously measure gait, balance, and mobility – at home or in clinic – using 140+ validated outcomes.
- Pick up what scales miss – Subtle functional decline often precedes clinical events. Early detection gives your team time to adapt and act.
- Backed by Mobilise-D – Our algorithms are aligned with EU and FDA recommendations to standardize digital mobility endpoints.
Streamline your MS trial with Clario’s expertise
Leverage 50+ years of neuroscience research, operational excellence, and regulatory insight
With the acquisition of NeuroRx, we enhance our imaging capabilities and expand full-service support, from site training to regulatory submission, ensuring a more efficient, faster, and decisive multiple sclerosis trial.
Related resources
Clario announces acquisition of imaging provider NeuroRx
March 17, 2025Advancing MS Clinical Trials: Integrating Medical Imaging, Precision Motion Analysis, and eCOA Data for Enhanced Outcomes Webinar replay
Clario joins forces with Mobilise-D to advance Digital Mobility Outcomes in clinical trials
August 13, 2024References
- Multiple Sclerosis International Federation (MSIF). Atlas of MS, (2023). https://www.atlasofms.org/